News >

Enzalutamide Improves Survival in Nonmetastatic CRPC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 12, 2020

Prostate Cancer
Enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) demonstrated a statistically significant improvement in overall survival (OS) compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to results of the final OS analysis of the phase III PROSPER trial.1

Enzalutamide was initially approved in 2012 as a treatment for men with metastatic CRPC following prior docetaxel therapy, and it was later expanded to be used prior to chemotherapy.

References          

  1. Xtandi (enzalutamide) demonstrates significant improvement in overall survival in phase 3 prosper trial of patients with NMCRPC [news release]: Tokyo, Japan and New York NY. Astellas Pharma, Inc., and Pfizer. Published February 11, 2020. Accessed February 12, 2020.           
  2. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Eng J Med. 2018;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
  3. Hussain M, Fizazi K, Saad F, et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). J Clin Oncol. 2018;36(suppl 6S; abstr 3).
  4. Tombal B, Saad F, Penson D, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x